Size | Price | Stock | Qty |
---|---|---|---|
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Acarbose (also known as BAY g 5421; trade names: Glucobay; Prandase; Precose) is an anti-diabetic drug used to treat diabetes mellitus type 2 and, in some countries, prediabetes by combining with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. It is a generic sold in Europe and China as Glucobay, in North America as Precose, and in Canada as Prandase. It is cheap and popular in China, but not in the U.S. One physician explains the use in the U.S. is limited because it is not potent enough to justify the side effects of diarrhea and flatulence.
ln Vitro |
The proliferation and migration of VSMC generated by TNF-α were reduced by acarbose (1, 2, and 3 μM) when dose and time were coupled. Acarbose (1, 2 and 3 μM) dose coupling decreased β-galactosidase and Ras expression while increasing p-AMPK expression in TNF-α-cleaved A7r5 [5].
|
---|---|
ln Vivo |
Rather than lowering body weight, acarbose (300 mg/60 kg body weight) lowers fasting blood pressure and modifies diabetic readings by supplementation. Acarbose dramatically reduces TNF-α and DM serum IL6[4]. Neointimal p-AMPK staining was dramatically raised while neointimal IL-6, TNF-α, and iNOS staining was significantly and dose-dependently lowered by acarbose (2.5 and 5.0 mg/kg). In HCD-fed rabbits, neointimal Ras and β-galactosidase expression were dramatically and dose-dependently decreased by acarbose (2.5 and 5.0 mg/kg) without causing weight loss [5].
|
References |
[1]. Yee HS, et al. A review of the safety and efficacy of acarbose in diabetes mellitus. Pharmacotherapy. 1996;16(5):792-805.
[2]. Hanefeld M, et al. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits [published correction appears in Expert Rev Cardiovasc Ther. 2009 Mar;7(3):330]. Expert Rev Cardiovasc Ther. 2008;6(2):153-163. [3]. Oki T, et al. Evaluation of alpha-glucosidase inhibition by using an immobilized assay system. Biol Pharm Bull. 2000;23(9):1084-1087. [4]. Zhang Q, et al. Acarbose Reduces Blood Glucose by Activating miR-10a-5p and miR-664 in Diabetic Rats. PLoS One. 2013 Nov 18;8(11):e79697. [5]. Chan KC, et al. Pleiotropic effects of acarbose on atherosclerosis development in rabbits are mediated via upregulating AMPK signals. Sci Rep. 2016 Dec 7;6:3864 |
Molecular Formula |
C25H43NO18
|
---|---|
Molecular Weight |
645.6048
|
Exact Mass |
645.247
|
CAS # |
56180-94-0
|
Related CAS # |
Acarbose sulfate;1221158-13-9
|
Appearance |
Solid powder
|
Density |
1.7±0.1 g/cm3
|
Boiling Point |
971.6±65.0 °C at 760 mmHg
|
Melting Point |
165-170ºC
|
Flash Point |
541.4±34.3 °C
|
Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
Index of Refraction |
1.689
|
LogP |
-4.16
|
InChi Key |
CEMXHAPUFJOOSV-XGWNLRGSSA-N
|
InChi Code |
InChI=1S/C25H43NO18/c1-7-13(26-9-2-8(3-27)14(33)18(37)15(9)34)17(36)20(39)24(41-7)44-23-12(6-30)42-25(21(40)19(23)38)43-22(11(32)5-29)16(35)10(31)4-28/h2,4,7,9-27,29-40H,3,5-6H2,1H3/t7-,9+,10+,11-,12-,13-,14-,15+,16-,17+,18+,19-,20-,21-,22-,23-,24-,25-/m1/s1
|
Chemical Name |
(2R,3R,4R,5R)-4-(((2R,3R,4R,5S,6R)-5-(((2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl)amino)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2,3,5,6-tetrahydroxyhexanal
|
Synonyms |
BAY-g-5421; BAY-g 5421; BAY g-5421; Acarbose; Glucobay; Prandase; Precose
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~100 mg/mL (~154.89 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (154.89 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.5489 mL | 7.7447 mL | 15.4895 mL | |
5 mM | 0.3098 mL | 1.5489 mL | 3.0979 mL | |
10 mM | 0.1549 mL | 0.7745 mL | 1.5489 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.